For human epidermal growth factor receptor 2 (HER2/neu)-overexpressing BC, the standard of care is systemic therapy using HER2/neu receptor targeting monoclonal antibodies such as trastuzumab and pertuzumab [5,6], in addition to other therapeutic agents and prompt surgical resection. This evidence concerns the gene ERBB2 and breast cancer.